{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:02:55Z","timestamp":1720569775778},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW Fortschr Med"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s15006-024-3937-9","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:06:27Z","timestamp":1720537587000},"page":"38-43","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Koinfektionen mit Hepatitisviren bei HIV","HIV and hepatitis B and hepatitis C coinfection: Treatment and practical experiences"],"prefix":"10.1007","volume":"166","author":[{"given":"Sven","family":"Breitschwerdt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Boesecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"3937_CR6563","doi-asserted-by":"crossref","unstructured":"Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-9","DOI":"10.1016\/j.jhep.2005.11.004"},{"key":"3937_CR6567","doi-asserted-by":"crossref","unstructured":"McGovern BH. The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. Antivir Ther. 2007;12:H3-13","DOI":"10.1177\/135965350701203S02"},{"key":"3937_CR6571","doi-asserted-by":"crossref","unstructured":"Kellerman SE et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:571-7","DOI":"10.1086\/377135"},{"key":"3937_CR6575","unstructured":"European AIDS Clinical Society Guidelines Version 11.0  O. http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html"},{"key":"3937_CR6579","doi-asserted-by":"crossref","unstructured":"Thio CL. Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients. Antivir Ther. 2007;12:H25-31","DOI":"10.1177\/135965350701203S04"},{"key":"3937_CR6684","doi-asserted-by":"crossref","unstructured":"Puoti M et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211-7","DOI":"10.1097\/00042560-200007010-00003"},{"key":"3937_CR6688","doi-asserted-by":"crossref","unstructured":"Thio CL, Seaberg EC, Skolasky R, Jr., Phair J, Visscher B, Mu\u00f1oz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921-6.","DOI":"10.1016\/S0140-6736(02)11913-1"},{"key":"3937_CR6692","doi-asserted-by":"crossref","unstructured":"Konopnicki D et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids. 2005;19:593-601","DOI":"10.1097\/01.aids.0000163936.99401.fe"},{"key":"3937_CR6696","doi-asserted-by":"crossref","unstructured":"Iloeje UH et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-86","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"3937_CR6583","doi-asserted-by":"crossref","unstructured":"Rana U et al. Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada? BMC Infect Dis. 2019;19:982","DOI":"10.1186\/s12879-019-4617-8"},{"key":"3937_CR6587","doi-asserted-by":"crossref","unstructured":"Stockdale AJ et al. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. Clin Infect Dis. 2015;61:883-91","DOI":"10.1093\/cid\/civ421"},{"key":"3937_CR6591","doi-asserted-by":"crossref","unstructured":"Marcellin P et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-75","DOI":"10.1016\/S0140-6736(12)61425-1"},{"key":"3937_CR6595","doi-asserted-by":"crossref","unstructured":"Dore GJ et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185-92","DOI":"10.1086\/380398"},{"key":"3937_CR6599","doi-asserted-by":"crossref","unstructured":"Bihl F, Martinetti G, Wandeler G, Weber R, Ledergeber B, Calmy A, et al. HBV genotypes and response to tenofovir disoproxil fumarate in HIV\/HBV-coinfected persons. BMC Gastroenterol. 2015;15:79","DOI":"10.1186\/s12876-015-0308-0"},{"key":"3937_CR6700","unstructured":"Trevi\u00f1o A et al. Newly Diagnosed HIV-1 Individuals in Spain since Year 2000. Non- B Subtypes, and Hepatitis C and B Virus Co-infections. 16th Conference on Retroviruses and Opportunistic Infections (CROI); Abstract 300, Montreal 2009"},{"key":"3937_CR6603","doi-asserted-by":"crossref","unstructured":"Boesecke C et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? Liver Int. 2015;35:2384-91","DOI":"10.1111\/liv.12848"},{"key":"3937_CR6704","doi-asserted-by":"crossref","unstructured":"Rockstroh JK et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992-1002","DOI":"10.1086\/432762"},{"key":"3937_CR6708","doi-asserted-by":"crossref","unstructured":"Benhamou Y et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-8","DOI":"10.1002\/hep.510300409"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-024-3937-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-024-3937-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-024-3937-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:17:43Z","timestamp":1720538263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-024-3937-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":18,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3937"],"URL":"https:\/\/doi.org\/10.1007\/s15006-024-3937-9","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"9 July 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die Autoren erkl\u00e4ren, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten lie\u00dfen. Sie legen folgende potenzielle Interessenkonflikte offen: S. Breitschwerdt: Reise- und Kongresskosten von Gilead, Viiv, Abbvie; C. Boesecke: Honorare f\u00fcr Vortr\u00e4ge und Beratungst\u00e4tigkeiten von Abbvie, Gilead, Janssen, MSD, ViiV, AstraZeneca, Bavarian Nordic.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Der Verlag erkl\u00e4rt, dass die inhaltliche Qualit\u00e4t des Beitrags durch zwei unabh\u00e4ngige Gutachten best\u00e4tigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere f\u00fcr Pr\u00e4parate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}